

**Title: Cell-free DNA (cfDNA) mutations from clonal hematopoiesis: Implications for interpretation of liquid biopsy tests**

**Authors:** Pedram Razavi<sup>1</sup>, Bob T. Li<sup>1</sup>, Chenlu Hou<sup>2</sup>, Ronglai Shen<sup>1</sup>, Oliver Venn<sup>2</sup>, Raymond S. Lim<sup>1</sup>, Earl Hubbell<sup>2</sup>, Ino De Bruijn<sup>1</sup>, Qinwen Liu<sup>2</sup>, Ravi Vijaya Satya<sup>2</sup>, Hui Xu<sup>2</sup>, Ling Shen<sup>2</sup>, Amy Sehnert<sup>2</sup>, Tara Maddala<sup>2</sup>, Michael F. Berger<sup>1</sup>, Alex Aravanis<sup>2</sup>, Jorge S. Reis Filho<sup>1</sup>, Mark Lee<sup>2</sup>, David B. Solit<sup>1</sup>, Jose Baselga<sup>1</sup>

**Affiliations:** <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, NY <sup>2</sup>GRAIL, Inc., Menlo Park, CA

**Disclosures:** Pedram Razavi received institutional research funding from GRAIL, Inc. Bob T. Li received institutional research funding from AstraZeneca, BioMed Valley Discoveries, GRAIL, Inc., Illumina, and Roche/Genentech; and received consulting/advisory fees from Biosceptre International, Roche, and Thermo Fisher Scientific. Chenlu Hou, Oliver Venn, Earl Hubbell, Qinwen Liu, Ravi Vijaya Satya, Hui Xu, Ling Shen, Amy Sehnert, Tara Maddala, and Alex Aravanis are or were employees of GRAIL, Inc. with stock or other ownership interests in the company. Michael F. Berger received research funding from Illumina, and consulting/advisory fees from Cancer Genetics and Sequenom. Jorge Reis-Filho received consulting/advisory fees from VolitionRX. Mark Lee is or was an employee of Boreal Genomics, Genomic Health, Google Life Sciences, and GRAIL, Inc.; has a leadership role with Boreal Genomics; has stock or other ownership interests in Boreal Genomics, Genomic Health, Google Life Sciences, and GRAIL, Inc.; and holds patents or other intellectual property, or has received royalties from, Genomic Health. David B. Solit received honoraria as well as consulting and/or advisory fees from Loxo and Pfizer. Jose Baselga has a leadership role (e.g., Board of Directors) with Infinity Pharmaceuticals, Varian Medical Systems, and GRAIL, Inc. (former board member); holds stock or other ownership interests in GRAIL, Inc., Infinity Pharmaceuticals, Juno Therapeutics, PMV Pharma, and Varian Medical Systems; and received consulting or advisory fees from Eli Lilly, Novartis, and GRAIL, Inc. The remaining authors have nothing to disclose.